World Journal of Surgery

, Volume 36, Issue 4, pp 714–722 | Cite as

Nine years of Experience with the Sentinel Lymph Node Biopsy in a Single Italian Center: A Retrospective Analysis of 1,050 Cases

  • Sergio BernardiEmail author
  • Serena Bertozzi
  • Ambrogio P. Londero
  • Francesco Giacomuzzi
  • Vito Angione
  • Cinzia Dri
  • Arnalda Carbone
  • Roberto Petri



This study aims to determine the prevalence and predictive factors for recurrence after sentinel lymph node biopsy (SLNB) and for sentinel lymph node positivity by SLNB in our population.


We followed up all SLNBs performed between 2002 and 2010 and analyzed data by R (version2.10.1), considering p < 0.05 significant.


Among 1,050 patients with SLNB, 23% (245/1050) underwent secondary axillary dissection (CALND). Axillary recurrence prevalence among patients with negative SLNB was 1% (6/805) at a mean follow-up of 54 months (±14), and 1.7% (95% CI 0.2–3.1%) after 6 years of follow-up, as all recurrences developed between the 3rd and the 6th years of follow-up. By multivariate analysis, axillary recurrence results correlated with large tumor size, high number of excised nodes, lymphovascular invasion, high grading, multifocality, Her-2 positivity, intraductal histology, and comedo-like necrosis. Moreover, SLNB positivity results correlated with young age, large tumor size, high number of excised nodes, negative history for second primary malignancies, lymphovascular invasion, and high grading.


Cancer characteristics represent important predictive factors for SLNB positivity, as well as for axillary recurrence in patients with negative SLNB, independently, by surgical and nonsurgical treatment. Therefore, cancer biological behavior and the patient’s hormonal profile should be evaluated with care to better tailor the follow-up of women with breast cancer.


Sentinel Node Sentinel Lymph Node Biopsy Lymphovascular Invasion Axillary Recurrence Sentinel Lymph Node Biopsy Positivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

268_2011_1420_MOESM1_ESM.doc (33 kb)
Supplementary material 1 (DOC 33 kb)


  1. 1.
    Rescigno J, Zampell JC, Axelrod D (2009) Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy. Ann Surg Oncol 16:687–696PubMedCrossRefGoogle Scholar
  2. 2.
    Johnson MT, Guidroz JA, Smith BJ et al (2009) A single institutional experience of factors affecting successful identification of sentinel lymph node in breast cancer patients. Surgery 146:671–676 discussion 676–677PubMedCrossRefGoogle Scholar
  3. 3.
    Dauphine C, Nemtsev D, Rosing D et al (2010) Axillary recurrence after sentinel lymph node biopsy for breast cancer. Am Surg 76:1127–1129PubMedGoogle Scholar
  4. 4.
    Cyr A, Gillanders WE, Aft RL et al (2010) Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden. Ann Surg Oncol 17(Suppl 3):303–311PubMedCrossRefGoogle Scholar
  5. 5.
    Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927–933PubMedCrossRefGoogle Scholar
  6. 6.
    Giuliano AE, McCall L, Beitsch P et al (2010) Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 252:426–432 discussion 432–433PubMedGoogle Scholar
  7. 7.
    Iannace C, Libero LD, Lepore M et al (2010) Prognostic and curative value of sentinel node in breast cancer. A 377 patients experience. Ann Ital Chir 81:103–111 discussion 112–113PubMedGoogle Scholar
  8. 8.
    Degnim AC, Zakaria S, Boughey JC et al (2010) Axillary recurrence in breast cancer patients with isolated tumor cells in the sentinel lymph node [AJCC N0(i+)]. Ann Surg Oncol 17:2685–2689PubMedCrossRefGoogle Scholar
  9. 9.
    Kim HJ, Son BH, Lim WS et al (2010) Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up. Ann Surg Oncol 17:2126–2131PubMedCrossRefGoogle Scholar
  10. 10.
    Sampol C, Giménez M, Torrecabota J et al (2010) Axillary recurrences after sentinel lymph node biopsy in initial breast cancer. Rev Esp Med Nucl 29:241–245PubMedCrossRefGoogle Scholar
  11. 11.
    Sanli I, Lemaire BMD, Muller AJ et al (2009) Axillary recurrence after negative sentinel lymph node biopsy: frequency and factors influencing recurrence on the long term. Breast J 15:236–241PubMedCrossRefGoogle Scholar
  12. 12.
    Kiluk J, Ly Q, Meade T et al (2009) Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up. Ann Surg Oncol 17:552–557CrossRefGoogle Scholar
  13. 13.
    Heuts EM, van der Ent FWC, Hulsewé KWE et al (2008) Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into the accuracy of sentinel node biopsy in breast cancer patients. Acta Chir Belg 108:203–207PubMedGoogle Scholar
  14. 14.
    Palesty JA, Foster JM, Hurd TC et al (2006) Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer. J Surg Oncol 93:129–132PubMedCrossRefGoogle Scholar
  15. 15.
    Torrenga H, Fabry H, van der Sijp JRM (2004) Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis. J Surg Oncol 88:4–7 discussion 7–8PubMedCrossRefGoogle Scholar
  16. 16.
    Bilimoria KY, Bentrem DJ, Hansen NM et al (2009) Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 27:2946–2953PubMedCrossRefGoogle Scholar
  17. 17.
    Langer I, Guller U, Hsu-Schmitz SF et al (2009) Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients. Eur J Surg Oncol 35:805–813PubMedCrossRefGoogle Scholar
  18. 18.
    Canavese G, Catturich A, Vecchio C et al (2009) Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 20:1001–1007PubMedCrossRefGoogle Scholar
  19. 19.
    Veronesi U, Galimberti V, Paganelli G et al (2009) Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer 45:1381–1388PubMedCrossRefGoogle Scholar
  20. 20.
    Sun JY, Ning LS (2008) Axillary skip metastases in breast cancer. Zhonghua Zhong Liu Za Zhi 30:352–355PubMedGoogle Scholar
  21. 21.
    Kim HJ, Son BH, Park EW et al (2009) Axillary recurrence after negative sentinel lymph node biopsy. Breast Cancer Res Treat 114:301–305PubMedCrossRefGoogle Scholar
  22. 22.
    Murray KL, Lambah PA, Anderson TJ et al (2002) Occult lymph node metastases in patients with “node negative” breast carcinoma treated with conservation surgery and axillary node sample and who subsequently developed axillary recurrence. Breast 11:249–251PubMedCrossRefGoogle Scholar
  23. 23.
    Schneebaum S, Stadler J, Cohen M et al (1998) Gamma probe-guided sentinel node biopsy—optimal timing for injection. Eur J Surg Oncol 24:515–519PubMedCrossRefGoogle Scholar
  24. 24.
    Borgstein PJ, Pijpers R, Comans EF et al (1999) Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186:275–283CrossRefGoogle Scholar
  25. 25.
    Verkooijen HM, Chatelain V, Fioretta G et al (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357PubMedCrossRefGoogle Scholar
  26. 26.
    Gauthier T, Mollard J, Fermeaux V et al (2009) Axillary recurrence after negative sentinel lymph node biopsy under local anesthesia in breast cancer. Eur J Surg Oncol 35:464–468PubMedCrossRefGoogle Scholar
  27. 27.
    Mustac E, An-Ilijaâ KM, Marijic B et al (2009) Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy. Int J Surg Pathol 18:36–41PubMedCrossRefGoogle Scholar
  28. 28.
    Chen JJ, Huang XY, Liu ZB et al (2009) Sentinel node biopsy and quality of life measures in a Chinese population. Eur J Surg Oncol 35:921–927PubMedCrossRefGoogle Scholar
  29. 29.
    Helms G, Kühn T, Moser L et al (2009) Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection—data from a prospective randomised trial. Eur J Surg Oncol 35:696–701PubMedCrossRefGoogle Scholar
  30. 30.
    Natarajan S, Taneja C, Cady B (2005) Evolution of lymphadenectomy in surgical oncology. Surg Oncol Clin N Am 14:447–459PubMedCrossRefGoogle Scholar
  31. 31.
    Winchester DP, Trabanino L, Lopez MJ (2005) The evolution of surgery for breast cancer. Surg Oncol Clin N Am 14:479–498PubMedCrossRefGoogle Scholar
  32. 32.
    Takács T, Paszt A, Szentpáli K et al (2008) Importance of sentinel lymph node biopsy in surgical therapy of in situ breast cancer. Pathol Oncol Res 15:329–333CrossRefGoogle Scholar
  33. 33.
    Gurleyik G, Gurleyik E, Aker F et al (2007) Lymphovascular invasion, as a prognostic marker in patients with invasive breast cancer. Acta Chir Belg 107:284–287PubMedGoogle Scholar
  34. 34.
    Weaver DL, Ashikaga T, Krag DN et al (2011) Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364:412–421PubMedCrossRefGoogle Scholar
  35. 35.
    Cote R, Giuliano AE, Hawes D et al. (2010) ACOSOG Z0010: a multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol (Meeting Abstracts) 28(18S):CRA504Google Scholar
  36. 36.
    Pazaiti A, Fentiman IS (2011) Which patients need an axillary clearance after sentinel node biopsy? Int J Breast Cancer 2011 Article ID 195892Google Scholar
  37. 37.
    Tjan-Heijnen VC, Pepels MJ, de Boer M et al (2009) Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): results from the MIRROR study. ASCO Meeting Abstracts 27(18S):CRA506Google Scholar
  38. 38.
    Leidenius M, Vironen J, Heikkilä P et al (2009) Influence of isolated tumor cells in xentinel nodes on outcome in small, node-negative (pT1N0M0) breast cancer. Ann Surg Oncol 17:252–262Google Scholar
  39. 39.
    Meretoja TJ, Leidenius MH, Heikkilä PS et al (2009) Sentinel node biopsy in breast cancer patients with large or multifocal tumors. Ann Surg Oncol 16:1148–1155PubMedCrossRefGoogle Scholar
  40. 40.
    Ejlertsen B, Jensen MB, Rank F et al (2009) Population-based study of peritumoral lymphovascular invasion and outcome among patients with operable breast cancer. J Natl Cancer Inst 101:729–735PubMedCrossRefGoogle Scholar
  41. 41.
    Yagata H, Harigaya K, Suzuki M et al (2003) Comedonecrosis is an unfavorable marker in node-negative invasive breast carcinoma. Pathol Int 53:501–506PubMedCrossRefGoogle Scholar
  42. 42.
    Bézu C, Coutant C, Antoine M et al (2009) Feasibility of the sentinel node biopsy in breast cancer in case of histological multifocality diagnosis. Gynecol Obstet Fertil 37:604–610PubMedCrossRefGoogle Scholar
  43. 43.
    Veronesi U, Orecchia R, Zurrida S et al (2005) Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol 16:383–388PubMedCrossRefGoogle Scholar
  44. 44.
    Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. J Am Med Assoc 305:569–575CrossRefGoogle Scholar
  45. 45.
    Pandit TS, Kennette W, Mackenzie L et al (2009) Lymphatic metastasis of breast cancer cells is associated with differential gene expression profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35:297–308PubMedGoogle Scholar
  46. 46.
    Oliveira LR, Jeffrey SS, Ribeiro-Silva A (2010) Stem cells in human breast cancer. Histol Histopathol 25:371–385PubMedGoogle Scholar
  47. 47.
    Colpaert C, Vermeulen P, Jeuris W et al (2001) Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 193:442–449PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2012

Authors and Affiliations

  • Sergio Bernardi
    • 1
    Email author
  • Serena Bertozzi
    • 1
  • Ambrogio P. Londero
    • 2
  • Francesco Giacomuzzi
    • 3
  • Vito Angione
    • 4
  • Cinzia Dri
    • 1
  • Arnalda Carbone
    • 5
  • Roberto Petri
    • 1
  1. 1.Department of SurgeryAzienda Ospedaliero-Univesitaria di UdineUdineItaly
  2. 2.Clinic of Obstetrics and GynecologyUniversity Hospital of UdineUdineItaly
  3. 3.Department of Nuclear MedicineAzienda Ospedaliero-Univesitaria di UdineUdineItaly
  4. 4.Department of PathologyAzienda Ospedaliero-Univesitaria di UdineUdineItaly
  5. 5.Department of RadiodiagnosticsAzienda Ospedaliero-Univesitaria di UdineUdineItaly

Personalised recommendations